Bio Innovation Conference | Agenda At-a-glance
page-template,page-template-full_width,page-template-full_width-php,page,page-id-10,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive

Agenda At-a-glance

october 7, 2019 •  bethesda north marriott hotel & conference center

    Monday, October 7, 2019

    7:30 am Registration Open | Exhibit Hall Open | Breakfast and Networking
    7:30 am-8:30 am BIO Partnering Meetings
    8:30 am-8:40 am Welcome and Opening Remarks
    8:45 am-9:45 am
    (concurrent panel sessions)


    Track 1

    Changing the Landscape for Cell and Gene Therapy
    Maryland’s Center of Excellence

    Margot Connor, Chief Executive Officer, RoosterBio

    Emily English, Ph.D., Chief Executive Officer, Gemstone Therapeutics
    Kimberly Noonan, Ph.D., Founder, Executive Vice President and Chief Scientific Officer, WindMIL Therapeutics
    William Rust, Ph.D., Chief Executive Officer and Co-Founder, Seraxis

    Track 2

    The Friends and Family Plan
    Experts discuss different levels of early stage fundraising

    Jeff Galvin, Chief Executive Officer and Founder, American Gene Technologies

    Judy CostelloManaging Director, Economic Development, BioHealth Innovation
    Henry Ahn, SBIR/STTR Program Director, National Science Foundation
    Joseph Naft, Director, Maryland Industrial Partnerships (MIPS) Program
    Paul Silber, Founding Principal, Blu Venture Investors

    10:00 am – 11:00 am
    Sponsored by Maxcyte

    Keynote Address
    Hopes for a Cure – Gene Therapy for Sickle Cell Anemia

    Keynote Speaker:
    John F. Tisdale, M.D., Chief, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health

    11:15 am-12:15 pm
    (concurrent panel sessions)


    Track 1

    Life Saving Therapies, Heart Stopping Prices
    Navigating Reimbursement

    Brian Abraham, Director,Market Access, Life Sciences, BDO

    Track 2

    Employment Opportunities Fulfilled
    The demand for life sciences job skills is growing rapidly in this region. Our roundtables will discuss opportunities and challenges while determining actions which can be taken to ensure workforce readiness and availability for the near-, mid- and long-term.

    Sarah Sheppard, Director of Education and Workforce, Office of Strategic Industries and Entrepreneurship, Maryland Department of Commerce

    Roundtable Discussion Leaders:
    Shiva Fritsch, Senior Vice President of Human Resources, REGENXBIO
    Brian Gaines, Chief Executive Officer, Learning Undefeated

    12:15 pm-1:30 pm
    Sponsored by Towson University

    Networking Lunch in the Exhibit Hall
    BIO Partnering Meetings

    1:30 pm-2:30 pm
    (concurrent panel sessions)


    Track 1

    Novel Therapies, Regulatory Realities

    Michael Druckman, Partner, Washington, D.C., Hogan Lovells

    David Feigal, M.D., MPH, Partner, NDA Partners
    Randy Prebula, Partner, Washington, D.C., Hogan Lovells

    Track 2

    Strategic Market Planning for Capital and Commercialization
    Experts discuss key considerations and timing for market assessments to drive strategic partnering options and optimized commercial launch success

    Sponsored by

    Steven Walker, MBA, MHA, Chief Business Officer and Commercial Strategist, Biologics Consulting

    Luis Gutierrez, Past President, Commercialization Services, Covance
    Ram Palanki, Pharm.D., Senior Vice President of Commercial Strategy and Operations, REGENXBIO
    Tyrell Rivers, Ph.D., Executive Director of Corporate Development, AstraZeneca

    2:45 pm-3:45 pm
    (concurrent panel sessions)


    Track 1

    New Frontiers of Biomanufacturing

    Martin Rosendale, Chief Executive Officer, Maryland Tech Council

    Jeffrey Hung, Ph.D.,Chief Commercial Officer, Vigene Biosciences, Inc.
    Christopher McDonald, Vice President of Manufacturing, Kite Pharma
    Jon Rowley, Ph.D., Founder and Chief Product Officer, RoosterBio
    Aaron Vernon
    , Vice President, Engineering and Supply Chain, Autolus

    Track 2

    Past Seed Stage to the Last Mile
    Experts discuss later stage fundraising opportunities

    Linda Segal, Principal, The McCormick Group

    Subhendu Basu, Ph.D.Chief Operating Officer, Adaptive Phage Therapeutics
    Diana Bernstein, Ph.D., Senior Associate, MRL Ventures
    Pete Buzy, President, Paragon Gene Therapy, Catalent Biologics
    R. Jacob Vogelstein, General Partner, Camden Partners

    4:00 pm-5:00 pm

    Keynote Address

    5:00 pm-6:00 pm

    Cocktail Reception

    STAY INFORMED. Join our mailing list to receive our email newsletter.